Abstract

THERAPEUTIC INNOVATIONS IN SEVERE FEVER WITH THROMBOCYTOPENIA SYNDROME, EMPHASIZING THE EFFICACY OF FAVIPIRAVIR

Evander James Kamupini*, Priyanka Keshri

.

Abstract

Severe Fever with Thrombocytopenia Syndrome (SFTS) is an emerging tick- borne viral infection caused by the SFTS virus (SFTSV) belonging to the Bunyaviridae family (Xu B, 2011) (Yu XJ, 2011). This syndrome is characterized by severe fever, thrombocytopenia, leukocytopenia, and multi-organ dysfunction, with high morbidity and mortality rates. The limited understanding of SFTS pathogenesis has prompted the exploration of antiviral agents and therapeutic innovations to improve patient outcomes. Antiviral agents play a pivotal role in the management of SFTS, aiming to reduce viral replication and mitigate the severity of the disease. Favipiravir, a broad-spectrum antiviral drug, has demonstrated promising efficacy against various RNA viruses, including SFTSV. Clinical studies and case reports have explored the use of favipiravir in SFTS patients, revealing potential benefits in terms of symptom alleviation and improved clinical outcomes (Furuta Y, 2009). In addition to favipiravir, this review discusses other therapeutic innovations in the management of SFTS. These innovations encompass immune-based therapies, such as convalescent plasma therapy and interferon-alpha, as well as supportive measures aimed at mitigating the severe manifestations of the disease. Furthermore, the potential role of emerging technologies, including diagnostic advancements and digital health solutions, in early detection and management of SFTS is explored. As the understanding of SFTS continues to evolve, this abstract underscores the importance of ongoing research and collaboration to further delineate the optimal therapeutic strategies for this emerging infectious disease. The insights provided herein contribute to the broader discourse on SFTS management and offer a foundation for future investigations into novel treatment modalities.

Keywords: Severe fever with thrombocytopenia, SFTS virus, Favipiravir (T-705), viral hemorrhagic fever, Ribavirin.